AnaptysBio, Inc. $ANAB Stake Increased by BNP Paribas Financial Markets

BNP Paribas Financial Markets increased its stake in AnaptysBio, Inc. (NASDAQ:ANAB) by 56.0% in the fourth quarter, Holdings Channel reports. The institutional investor owned 164,823 shares of the biotechnology company’s stock after acquiring an additional 59,160 shares during the quarter. BNP Paribas Financial Markets’ holdings in AnaptysBio were worth $7,991,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also made changes to their positions in the stock. Larson Financial Group LLC grew its stake in AnaptysBio by 54.6% in the third quarter. Larson Financial Group LLC now owns 1,340 shares of the biotechnology company’s stock worth $41,000 after purchasing an additional 473 shares in the last quarter. Bessemer Group Inc. grew its stake in AnaptysBio by 950.0% in the third quarter. Bessemer Group Inc. now owns 1,428 shares of the biotechnology company’s stock worth $44,000 after purchasing an additional 1,292 shares in the last quarter. Tower Research Capital LLC TRC grew its stake in AnaptysBio by 175.0% in the second quarter. Tower Research Capital LLC TRC now owns 2,164 shares of the biotechnology company’s stock worth $48,000 after purchasing an additional 1,377 shares in the last quarter. Osaic Holdings Inc. grew its stake in AnaptysBio by 11,630.0% in the second quarter. Osaic Holdings Inc. now owns 2,346 shares of the biotechnology company’s stock worth $52,000 after purchasing an additional 2,326 shares in the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. grew its stake in AnaptysBio by 24.3% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,345 shares of the biotechnology company’s stock worth $65,000 after purchasing an additional 263 shares in the last quarter.

Insider Buying and Selling at AnaptysBio

In other AnaptysBio news, CEO Daniel Faga sold 17,679 shares of the business’s stock in a transaction on Friday, March 27th. The shares were sold at an average price of $61.61, for a total transaction of $1,089,203.19. Following the completion of the sale, the chief executive officer owned 495,965 shares in the company, valued at $30,556,403.65. The trade was a 3.44% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director John P. Schmid sold 20,645 shares of the business’s stock in a transaction on Monday, March 30th. The shares were sold at an average price of $56.11, for a total transaction of $1,158,390.95. Following the sale, the director owned 31,622 shares of the company’s stock, valued at approximately $1,774,310.42. The trade was a 39.50% decrease in their position. The disclosure for this sale is available in the SEC filing. 33.50% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

ANAB has been the subject of a number of research reports. Barclays lifted their price target on AnaptysBio from $63.00 to $75.00 and gave the stock an “overweight” rating in a research note on Wednesday, May 13th. Weiss Ratings downgraded AnaptysBio from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Wednesday, May 13th. Wedbush lifted their price target on AnaptysBio from $60.00 to $75.00 and gave the stock an “outperform” rating in a research note on Thursday, March 12th. UBS Group boosted their target price on shares of AnaptysBio from $60.00 to $76.00 and gave the company a “buy” rating in a research note on Wednesday, May 13th. Finally, Stifel Nicolaus boosted their target price on shares of AnaptysBio from $56.00 to $85.00 and gave the company a “buy” rating in a research note on Thursday, March 5th. Ten research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $79.18.

AnaptysBio Price Performance

ANAB stock opened at $51.63 on Wednesday. AnaptysBio, Inc. has a 1-year low of $11.40 and a 1-year high of $72.36. The firm has a fifty day moving average price of $60.44 and a two-hundred day moving average price of $54.20. The firm has a market cap of $1.50 billion, a price-to-earnings ratio of -47.81 and a beta of 0.72.

AnaptysBio (NASDAQ:ANAB) last released its earnings results on Tuesday, May 12th. The biotechnology company reported ($1.84) earnings per share for the quarter, missing the consensus estimate of ($0.64) by ($1.20). AnaptysBio had a negative net margin of 11.53% and a negative return on equity of 1,101.24%. The business had revenue of $25.56 million for the quarter, compared to the consensus estimate of $18.86 million. As a group, analysts expect that AnaptysBio, Inc. will post -0.93 EPS for the current fiscal year.

AnaptysBio declared that its Board of Directors has initiated a stock repurchase plan on Friday, March 27th that permits the company to buyback $100,000.00 billion in shares. This buyback authorization permits the biotechnology company to buy up to 5,352,316.2% of its shares through open market purchases. Shares buyback plans are usually an indication that the company’s board believes its stock is undervalued.

About AnaptysBio

AnaptysBio, Inc is a clinical-stage biotechnology company focused on the discovery and development of therapeutic antibody product candidates in immunology and inflammation. Founded in 2012 and headquartered in San Diego, California, AnaptysBio leverages a proprietary somatic hypermutation platform to rapidly generate and refine human antibodies with optimized efficacy and safety profiles. The company’s technology is designed to accelerate target validation and candidate selection across a range of immune-mediated conditions.

The company’s pipeline includes multiple clinical-stage programs addressing dermatological and inflammatory disorders.